RhumbLine Advisers’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $643K | Sell |
|
|||||
|
2025
Q2 | $615K | Buy |
|
|||||
|
2025
Q1 | $611K | Buy |
|
|||||
|
2024
Q4 | $433K | Buy |
|
|||||
|
2024
Q3 | $582K | Sell |
|
|||||
|
2024
Q2 | $627K | Buy |
|
|||||
|
2024
Q1 | $561K | Buy |
|
|||||
|
2023
Q4 | $556K | Buy |
|
|||||
|
2023
Q3 | $403K | Buy |
|
|||||
|
2023
Q2 | $376K | Buy |
|
|||||
|
2023
Q1 | $305K | Buy |
|
|||||
|
2022
Q4 | $254K | Buy |
|
|||||
|
2022
Q3 | $544K | Buy |
|
|||||
|
2022
Q2 | $341K | Buy |
|
|||||
|
2022
Q1 | $326K | Buy |
|
|||||
|
2021
Q4 | $252K | Sell |
|
|||||
|
2021
Q3 | $333K | Buy |
|
|||||
|
2021
Q2 | $435K | Sell |
|
|||||
|
2021
Q1 | $595K | Buy |
|
|||||
|
2020
Q4 | $361K | Buy |
|
|||||
|
2020
Q3 | $198K | Sell |
|
|||||
|
2020
Q2 | $214K | Buy |
|
|||||
|
2020
Q1 | $82K | Sell |
|
|||||
|
2019
Q4 | $194K | Buy |
|
|||||
|
2019
Q3 | $123K | Sell |
|
|||||
|
2019
Q2 | $237K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $9K | Hold |
|
|||||
|
2015
Q4 | $49K | Buy |
|